↓ Skip to main content

Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma

Overview of attention for article published in BMC Cancer, June 2015
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (82nd percentile)

Mentioned by

1 blog
1 patent


39 Dimensions

Readers on

43 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Combined inhibition of the cell cycle related proteins Wee1 and Chk1/2 induces synergistic anti-cancer effect in melanoma
Published in
BMC Cancer, June 2015
DOI 10.1186/s12885-015-1474-8
Pubmed ID

Gry Irene Magnussen, Elisabeth Emilsen, Karianne Giller Fleten, Birgit Engesæter, Viola Nähse-Kumpf, Roar Fjær, Ana Slipicevic, Vivi Ann Flørenes


Malignant melanoma has an increasing incidence rate and the metastatic disease is notoriously resistant to standard chemotherapy. Loss of cell cycle checkpoints is frequently found in many cancer types and makes the cells reliant on compensatory mechanisms to control progression. This feature may be exploited in therapy, and kinases involved in checkpoint regulation, such as Wee1 and Chk1/2, have thus become attractive therapeutic targets. In the present study we combined a Wee1 inhibitor (MK1775) with Chk1/2 inhibitor (AZD7762) in malignant melanoma cell lines grown in vitro (2D and 3D cultures) and in xenografts models. Our in vitro studies showed that combined inhibition of Wee1 and Chk1/2 synergistically decreased viability and increased apoptosis (cleavage of caspase 3 and PARP), which may be explained by accumulation of DNA-damage (increased expression of γ-H2A.X) - and premature mitosis of S-phase cells. Compared to either inhibitor used as single agents, combined treatment reduced spheroid growth and led to greater tumour growth inhibition in melanoma xenografts. These data provide a rationale for further evaluation of the combination of Wee1 and Chk1/2 inhibitors in malignant melanoma.

Mendeley readers

The data shown below were compiled from readership statistics for 43 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Japan 1 2%
Spain 1 2%
Unknown 41 95%

Demographic breakdown

Readers by professional status Count As %
Researcher 13 30%
Student > Ph. D. Student 9 21%
Student > Master 7 16%
Other 3 7%
Professor > Associate Professor 2 5%
Other 3 7%
Unknown 6 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 13 30%
Biochemistry, Genetics and Molecular Biology 12 28%
Pharmacology, Toxicology and Pharmaceutical Science 3 7%
Medicine and Dentistry 3 7%
Chemistry 1 2%
Other 1 2%
Unknown 10 23%

Attention Score in Context

This research output has an Altmetric Attention Score of 8. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 October 2018.
All research outputs
of 14,821,238 outputs
Outputs from BMC Cancer
of 5,600 outputs
Outputs of similar age
of 339,448 outputs
Outputs of similar age from BMC Cancer
of 1 outputs
Altmetric has tracked 14,821,238 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,600 research outputs from this source. They receive a mean Attention Score of 4.0. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 339,448 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them